Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker GRCE
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 3,087 | $1.77 | $5,478 Buy | Form 4 ↗ |
| Nov 4, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 5,027 | $1.80 | $9,060 Buy | Form 4 ↗ |
| Nov 3, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 10,328 | $1.79 | $18.5K Buy | Form 4 ↗ |
| Oct 26, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 66,411 | $1.77 | $117.4K Buy | Form 4 ↗ |
| Oct 22, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 21,390 | $1.93 | $41.2K Buy | Form 4 ↗ |
| Oct 19, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 4,256 | $1.88 | $8,001 Buy | Form 4 ↗ |
| Oct 16, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 36,347 | $1.89 | $68.8K Buy | Form 4 ↗ |
| Oct 15, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 23,485 | $1.95 | $45.7K Buy | Form 4 ↗ |
| Oct 14, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 11,233 | $1.93 | $21.7K Buy | Form 4 ↗ |
| Sep 23, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 5,318 | $2.10 | $11.2K Buy | Form 4 ↗ |
| Sep 21, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 9,771 | $2.10 | $20.5K Buy | Form 4 ↗ |
| Sep 9, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 5,836 | $2.09 | $12.2K Buy | Form 4 ↗ |
| Sep 9, 2026 | Prashant Kohli Chief Executive Officer, Director | GRCE Grace Therapeutics, Inc. | Buy | 100,000 | $2.14 | $214.0K Buy | Form 4 ↗ |
| Sep 8, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 9,393 | $2.10 | $19.7K Buy | Form 4 ↗ |
| Aug 14, 2026 | Opaleye Management Inc. 10% owner | GRCE Grace Therapeutics, Inc. | Buy | 11,608 | $2.09 | $24.3K Buy | Form 4 ↗ |
15 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:25 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances